Currently, Soleno Therapeutics Inc [SLNO] is trading at $63.76, down -2.75%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SLNO shares have gain 7.68% over the last week, with a monthly amount glided 12.40%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Soleno Therapeutics Inc [NASDAQ: SLNO] stock has seen the most recent analyst activity on October 07, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $125. Previously, Wells Fargo started tracking the stock with Overweight rating on August 20, 2025, and set its price target to $123. On June 23, 2025, TD Cowen initiated with a Buy rating and assigned a price target of $110 on the stock. Stifel reiterated its recommendation of a Buy but $74 remained the price target by the analyst firm on December 02, 2024. Robert W. Baird reiterated a Outperform rating for this stock on December 02, 2024, but kept the price target unchanged to $72. In a note dated September 03, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $70 on this stock.
This stock has fluctuated between a low of $41.50 and a high of $90.32 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $123 within the next 12 months. Soleno Therapeutics Inc [NASDAQ: SLNO] shares were valued at $63.76 at the most recent close of the market. An investor can expect a potential return of 92.91% based on the average SLNO price forecast.
Analyzing the SLNO fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -5.87%, Pretax Profit Margin comes in at -5.54%, and Net Profit Margin reading is -5.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.54, Equity is -0.74 and Total Capital is -0.62. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Soleno Therapeutics Inc [NASDAQ:SLNO] is 15.13. As well, the Quick Ratio is 15.01, while the Cash Ratio is 3.65. Considering the valuation of this stock, the price to sales ratio is 103.74, the price to book ratio is 13.39.
Transactions by insiders
Recent insider trading involved Abingworth Bioventures VII LP, Shareholder, that happened on Aug 11 ’25 when 1.35 million shares were purchased. Hirano Patricia C completed a deal on Jul 01 ’25 to sell 3830.0 shares. Meanwhile, Officer PATRICIA HIRANO bought 3830.0 shares on Jul 01 ’25.
